555win cung cấp cho bạn một cách thuận tiện, an toàn và đáng tin cậy [xstd 30]
Jul 1, 2025 · Welcome to our dedicated page for Geron SEC filings (Ticker: GERN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Some specific ways to access filings based on time, type, or other categories.
Nov 7, 2024 · Jim Ziegler appointed as Executive Vice President, Chief Commercial Officer in September 2024, to spearhead Geron’s global commercial strategy and operations, lead the commercial organization and be responsible for driving growth of RYTELO.
Geron Corporation, a biopharmaceutical company, develops biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, and diabetes. It develops a range of anti-cancer therapies based on telomerase inhibitors and telomerase therapeutic vaccines; and diagnostics based on telomerase detection, as well as …
Explore Research & Development Pipeline Partnering Patients Browse Publications Corporate profile Press releases Events Learn About Leadership Culture History Follow ...
Aug 8, 2025 · 1 2 3 4 5 Next › Last »Displaying 1 - 10 of 45 results
2024 FY Annual report, 10-K SEC filing by Geron on 26 Feb 25, 5:33pm
Feb 26, 2025 · Analyze up to 10 years of full 10K Annual Reports and Quarterly 10Q SEC filings for Geron Corp (GERN) using our online tools.
Further information concerning shareholdings of our executive officers, directors and principal stockholders is incorporated by reference in Part III, Item 12 of this annual report on Form 10‑K.
Skip to main content Research & Development Patients Medicines Investors & Media About Careers Press Releases Events Stock Information Corporate Governance SEC Filings Analyst Coverage FAQs Publications
Dec 31, 2024 · FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .
Further information concerning shareholdings of our executive officers, directors and principal stockholders is incorporated by reference in Part III, Item 12 of this annual report on Form 10‐K.
Bài viết được đề xuất: